Clinical trial
A Prospective, Multicenter, Open Label Single Arm Phase IV Clinical Trial to Assess Safety of ImbruvicaTM (Ibrutinib Capsules 140 mg) in Indian Patients With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion
NCT03190330 is registered in ClinicalTrials.gov with Johnson & Johnson Private Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Multicenter, Open Label Single Arm Phase IV Clinical Trial to Assess Safety of ImbruvicaTM (Ibrutinib Capsules 140 mg) in Indian Patients With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion
- Lead sponsor
- Johnson & Johnson Private Limited
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- June 26, 2019
- Completion date
- May 3, 2023
- Enrollment
- 75 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.